BOTOX® Prophylaxis in Patients With Chronic Migraine

Allergan

Status: Completed

Conditions: Migraine Disorders

Treatments: Biological: botulinum toxin Type A

Study type: Observational

Funder types: Industry

Identifiers

NCT01432379

191622-110

Details and patient eligibility

About

This is a post authorization observational study to monitor the utilization practices and describe the safety profile of BOTOX® in clinical practice for the prophylactic treatment of headaches in adult patients with chronic migraine.

Enrollment: 1,168 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of chronic migraine
• Willing to use BOTOX® as preventative treatment for migraine

Exclusion criteria

• None

Trial design

1,168 participants in 1 patient group

botulinum toxin Type A

Description:

155-195 U of botulinum toxin Type A administered intramuscularly in the face, head, and neck areas as directed by physician (approximately every 12 weeks) for 1 year.

Treatment:

Biological: botulinum toxin Type A